Autor segons l'article: Ferre-Vallverdu, M; Ligero, C; Vidal-Perez, R; Martinez-Rubio, A; Vinolas, X; Alegret, JM
Departament: Medicina i Cirurgia
Autor/s de la URV: Alegret Colomé, Josep Maria / Ferré Vallverdú, Maria / Ligero Ferrer, Maria Carmen
Paraules clau: Treatment response Symptoms improvement Symptom Spain Sinus rhythm Retrospective study Retrospective studies Registry Quality-of-life Propafenone Procedures Prediction Pathophysiology Outcomes Nyha functional class New york heart association class Middle aged Management Male Major clinical study Humans Human Follow up Flecainide Female European heart rhythm association score Electric countershock Ehra score Echocardiography Disease severity Disease exacerbation Disease association Dipeptidyl carboxypeptidase inhibitor Digoxin Controlled study Clinical practice Clinical feature Clinical assessment tool Cardioversion Cardiac patient Calcium channel blocking agent Beta adrenergic receptor blocking agent Atrial fibrillation Association Article Antiarrhythmic agent Angiotensin receptor antagonist Amiodarone Aged Adult
Resum: Background: The European Heart Rhythm Association (EHRA) score is a proven and validated tool for assessing the symptoms of atrial fibrillation (AF). Little is known about the variables related to this score and how it changes after cardioversion.
Methods: We analyzed 744 patients undergoing elective cardioversion in whom AF-related symptoms were assessed at baseline and after 6 months of follow-up using the EHRA score. We assessed the association between the EHRA score and other clinical and echocardiographic variables at baseline and after 6 months of follow-up.
Results: At 6 months of follow-up, we observed a reduction in the EHRA score in 50% and worsening in 2.8% of patients who remained in sinus rhythm (SR) compared with 34.6% and 11.3%, respectively, of patients with AF episodes (p<0.0001). Patients who maintained SR at 6 months were less symptomatic than those with AF (EHRA score 1.13 +/- 0.35 vs 1.42 +/- 0.59; p<0.0001). The independent predictors for reduction in the EHRA score after cardioversion were NYHA >= II at baseline and maintenance of SR (p<0.0001).
Conclusion: The greatest improvement in AF-related symptoms was in patients who remained in SR at 6 months after cardioversion and in patients with worse NYHA functional class at baseline.
Àrees temàtiques: Saúde coletiva Planejamento urbano e regional / demografia Odontología Nutrição Medicine (miscellaneous) Medicina iii Medicina ii Medicina i Interdisciplinar Geriatrics and gerontology Geriatrics & gerontology General medicine Enfermagem Educação física Ciências biológicas ii Ciências biológicas i Ciências ambientais Ciência de alimentos Biotecnología
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: maria.ferrev@urv.cat mariacarmen.ligero@urv.cat mariacarmen.ligero@urv.cat josepmaria.alegret@urv.cat
Identificador de l'autor: 0000-0002-6117-5512
Data d'alta del registre: 2024-07-27
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Clinical Interventions In Aging. 16 739-745
Referència de l'ítem segons les normes APA: Ferre-Vallverdu, M; Ligero, C; Vidal-Perez, R; Martinez-Rubio, A; Vinolas, X; Alegret, JM (2021). Improvement in Atrial Fibrillation-Related Symptoms After Cardioversion: Role of NYHA Functional Class and Maintenance of Sinus Rhythm. Clinical Interventions In Aging, 16(), 739-745. DOI: 10.2147/CIA.S305619
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications
Repositori URV